Transgenic Mouse, ICSI and IVF Core

项目摘要/摘要-转基因小鼠、ICSI和试管受精核心 在IBR Cobre第一阶段建立了转基因小鼠核心，基于新的 转座酶介导的基因传递和靶向技术是由我们的一位同事在我们研究所开发的 调查人员。在最初的四年中，核心组织在实现成为 在十五年内独立支持。我们已经积累了大量的设备用于 小鼠配子和胚胎培养的显微操作，并聘请了一名经验丰富的经理来 领导核心实验室。在建立核心之前，我们咨询了两个已建立的转基因核心， 其中之一是内华达大学支持的科布雷。IBR核心已经取得了很好的进展， 培育了36个转基因小鼠品系，并开发了科布雷研究人员提供的新服务 要求核心非常适合提供。核心继续开发新的基因递送 技术，包括在靶向基因插入方面取得重大进展。因此，核心做出了贡献 为加强机构的研究基础设施，向科布雷调查人员提供 转基因小鼠等服务，研究开发，培养下一代科学家。 在此第二阶段应用程序中，我们建议通过扩展服务IT来增强和改造Core 提供通过：(1)继续研究和开发，以提高转基因小鼠的效率 生产，以及(2)由该大学资助的动物和实验室空间的重大翻新 IBR Cobre的机构支持。核心将直接支持四位新的Cobre项目负责人。 由于这一扩展，我们将其更准确地命名为：转基因小鼠、ICSI和试管受精(TMII) 核心。斯特凡·莫伊西亚迪博士，开发基因插入新技术的小组负责人，以及 他是一名毕业于独立的第一阶段初级调查员，将成为TMII核心主任。 这些目标将通过以下具体目标来实现：具体目标1.改进TMII核心 通过扩大服务、发展基础设施和翻新核心实验室。《核心》 将继续使用传统技术提供转基因小鼠，同时纳入迅速出现的 该领域的新技术，既来自我们自己的团队，也来自其他人。我们还将增加新的服务，如 作为第二阶段的ICSI和试管受精。耗资400万美元对UH Manoa Varium进行翻修将使 转基因小鼠的生产效率将大大提高。这将是朝着发展的重要一步。 我们在第二阶段的独立性。具体目标2。通过创新增强和改造IBR TMII核心 在IBR眼镜蛇第一阶段开发的技术和基因传递系统的持续开发。 TMII Core将在DR的指导下，在第二阶段继续开发基因插入技术。 莫伊沙迪。

PROJECT SUMMARY/ABSTRACT - Transgenic Mouse, ICSI and IVF Core The Transgenic Mouse Core was established during Phase I of the IBR COBRE based on novel transposase-mediated gene delivery and targeting technology developed at our institute by one of our COBRE investigators. During the first four years, the Core made significant progress towards the goal of becoming independently supported within fifteen years. We have accumulated a large array of equipment for micromanipulation of mouse gametes and embryo culture, and have recruited an experienced manager to head the Core laboratory. Before establishing the Core, we consulted with two established transgenic cores, one of which was COBRE supported at the University of Nevada. The IBR Core has made excellent progress, having produced 36 transgenic mouse lines, and developed new services that the COBRE investigators required that the Core was well suited to provide. The Core continued the development of novel gene delivery technology, including making significant progress on targeted gene insertion. Thus, the Core has contributed to the enhancement of the institution's research infrastructure by providing the COBRE investigators with transgenic mice and other services, research development, and training the next generation of scientists. In this Phase II application, we propose to enhance and transform the Core by expanding the services it provides through: (1) continued research and development to increase the efficiency of transgenic mouse production, and (2) a major renovation of animal and laboratory space that is being funded by the university as institutional support of the IBR COBRE. The Core will directly support four new COBRE Project Leaders. Because of this expansion, we have more accurately named it: the Transgenic Mouse, ICSI and IVF (TMII) Core. Dr. Stefan Moisyadi, the leader of the group that developed the new technology for gene insertion, and who was a Phase I junior investigator that graduated to independence, will become the TMII Core Director. These goals will be achieved through the following Specific Aims: Specific Aim 1. Improve the TMII Core through expansion of services, infrastructure development and renovation of the core laboratories. The Core will continue to provide transgenic mice using conventional technologies while incorporating rapidly emerging new technologies in the field, both from our own group and from others. We will also add new services such as ICSI and IVF to Project Leaders in Phase II. A $4 million renovation to the UH Manoa vivarium will allow transgenic mice to be produced much more efficiently. This will be an important step towards the development of our independence in Phase II. Specific Aim 2. Enhance and transform the IBR TMII Core through novel technology developed in Phase I of the IBR COBRE and the continued development of gene delivery systems. The TMII Core will continue to develop gene insertion technology during Phase II under the direction of Dr. Moisyadi.